Banque Transatlantique SA Purchases 1,867,525 Shares of Pfizer Inc. $PFE

Banque Transatlantique SA boosted its position in Pfizer Inc. (NYSE:PFE) by 2,787.1% during the first quarter, Holdings Channel reports. The fund owned 1,934,531 shares of the biopharmaceutical company’s stock after acquiring an additional 1,867,525 shares during the period. Pfizer comprises 0.8% of Banque Transatlantique SA’s holdings, making the stock its 23rd biggest holding. Banque Transatlantique SA’s holdings in Pfizer were worth $45,302,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in PFE. Pacer Advisors Inc. increased its stake in Pfizer by 856.8% in the first quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock valued at $508,164,000 after acquiring an additional 17,957,928 shares during the last quarter. Amundi increased its stake in Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the last quarter. Nuveen LLC bought a new position in Pfizer in the first quarter valued at $389,861,000. Starboard Value LP bought a new position in Pfizer in the fourth quarter valued at $407,730,000. Finally, Goldman Sachs Group Inc. increased its stake in Pfizer by 51.9% in the first quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after acquiring an additional 9,041,990 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 0.7%

NYSE PFE opened at $24.94 on Wednesday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The stock has a market capitalization of $141.77 billion, a PE ratio of 13.26, a PEG ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The business’s 50-day moving average is $24.82 and its 200 day moving average is $24.37.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.Pfizer’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. HSBC reduced their price objective on Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday, May 19th. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 6th. Berenberg Bank reduced their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating on the stock in a research note on Thursday, May 29th. Finally, Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.